NCATS matches academic research groups with selected assets from industry, as part of the New Therapeutic Uses program’s NIH-Industry Partnerships initiative. The goal is to use molecules that have already undergone significant research and development by pharmaceutical companies to more quickly advance new treatments for patients.
Awarded projects support pre-clinical validation studies, clinical feasibility studies or proof-of-concept clinical trials to test whether the selected assets may be effective against a previously unexplored disease.
In September 2016, NCATS announced a funding opportunity to explore a potential new use of an existing investigational therapy, Food and Drug Administration-approved drug, or licensed biologic. Through the Bench-to-Clinic Repurposing initiative, NCATS will support pre-clinical studies, clinical feasibility studies or proof-of-concept clinical trials to test the utility of an independent crowdsourcing effort orcomputational algorithm to predict new uses of a drug or biologic.